Literature DB >> 8294873

Macrophage inflammatory protein 1 alpha, interleukin 3 and diffusible marrow stromal factors maintain human hematopoietic stem cells for at least eight weeks in vitro.

C M Verfaillie1, P M Catanzarro, W N Li.   

Abstract

Factors that induce proliferation of the human hematopoietic stem cell are ill-defined. Primitive hematopoietic progenitors can be maintained and differentiate in stroma-dependent, long-term bone marrow cultures (LTBMC), originally described by Dexter et al. (Dexter, T. M., L. H. Coutinho, E. Spooncer, C. M. Heyworth, C. P. Daniel, R. Schiro, J. Chang, and T. D. Allen. 1990. Molecular Control of Haemopoiesis). However, 70-80% of primitive progenitors capable of reinitiating secondary stromal cultures (LTBMC-initiating cells [IC]) are lost over a period of 5 wk in such cultures. We have recently described a novel "stroma-noncontact" culture system, in which hematopoietic progenitors are separated from the stromal layer by a 0.4-micron microporous filter membrane. Primitive progenitors in such cultures can not only differentiate into committed progenitors, but are also maintained to a greater extent than in "Dexter" cultures. However, still only 50% of the originally seeded LTBMC-IC are recovered at week 5. Since maintenance of primitive progenitors may depend not only on growth-promoting factors but also on factors that inhibit differentiation and/or proliferation, we evaluated the effect of macrophage inflammatory protein 1 alpha (MIP-1 alpha) or "stem cell inhibitor" in combination with the growth-inducing factor interleukin 3 (IL-3) on the recovery of LTBMC-IC from stroma-noncontact cultures. We demonstrate that addition of MIP-1 alpha alone to stroma-noncontact cultures does not change the number of LTBMC-IC present after 8 wk, indicating that this factor may not directly inhibit or stimulate proliferation of primitive progenitors. Addition of the growth stimulatory cytokine, IL-3, alone results in exhaustion of LTBMC-IC after 8 wk of culture, possibly as a result of their terminal differentiation. However, LTBMC-IC can be maintained for at least 8 wk when grown in stroma-noncontact cultures supplemented with both MIP-1 alpha plus IL-3. This effect depends on soluble (ill-defined) stromal factors, and results from a direct interaction of these cytokines with the progenitor population or its progeny, but not the stroma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8294873      PMCID: PMC2191371          DOI: 10.1084/jem.179.2.643

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  24 in total

1.  Direct contact between human primitive hematopoietic progenitors and bone marrow stroma is not required for long-term in vitro hematopoiesis.

Authors:  C M Verfaillie
Journal:  Blood       Date:  1992-06-01       Impact factor: 22.113

2.  Macrophage inflammatory protein 1 modulates macrophage function.

Authors:  T J Fahey; K J Tracey; P Tekamp-Olson; L S Cousens; W G Jones; G T Shires; A Cerami; B Sherry
Journal:  J Immunol       Date:  1992-05-01       Impact factor: 5.422

3.  Macrophage-inflammatory protein protects multipotent hematopoietic cells from the cytotoxic effects of hydroxyurea in vivo.

Authors:  B I Lord; T M Dexter; J M Clements; M A Hunter; A J Gearing
Journal:  Blood       Date:  1992-05-15       Impact factor: 22.113

4.  Leukemia inhibitory factor/human interleukin for DA cells: a growth factor that stimulates the in vitro development of multipotential human hematopoietic progenitors.

Authors:  C Verfaillie; P McGlave
Journal:  Blood       Date:  1991-01-15       Impact factor: 22.113

5.  Enhancement of murine hematopoiesis by synergistic interactions between steel factor (ligand for c-kit), interleukin-11, and other early acting factors in culture.

Authors:  K Tsuji; S D Lyman; T Sudo; S C Clark; M Ogawa
Journal:  Blood       Date:  1992-06-01       Impact factor: 22.113

6.  Role of c-kit ligand in the expansion of human hematopoietic progenitor cells.

Authors:  J Brandt; R A Briddell; E F Srour; T B Leemhuis; R Hoffman
Journal:  Blood       Date:  1992-02-01       Impact factor: 22.113

7.  Use of 5-fluorouracil to analyze the effect of macrophage inflammatory protein-1 alpha on long-term reconstituting stem cells in vivo.

Authors:  V F Quesniaux; G J Graham; I Pragnell; D Donaldson; S D Wolpe; N N Iscove; B Fagg
Journal:  Blood       Date:  1993-03-15       Impact factor: 22.113

8.  Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor.

Authors:  K Neote; D DiGregorio; J Y Mak; R Horuk; T J Schall
Journal:  Cell       Date:  1993-02-12       Impact factor: 41.582

Review 9.  Transforming growth factors-beta as regulators of cellular growth and phenotype.

Authors:  M Laiho; J Keski-Oja
Journal:  Crit Rev Oncog       Date:  1992

Review 10.  Molecular aspects of a negative regulator of haemopoiesis.

Authors:  M Plumb; G J Graham; M Grove; A Reid; I B Pragnell
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640

View more
  9 in total

1.  Macrophage inflammatory protein-1alpha (MIP-1alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1.

Authors:  Y Lu; K Q Xin; K Hamajima; T Tsuji; I Aoki; J Yang; S Sasaki; J Fukushima; T Yoshimura; S Toda; E Okada; K Okuda
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

2.  Ex vivo expansion of primitive hematopoietic cells for cellular therapies: An overview.

Authors:  T A McAdams; C E Sandstrom; W M Miller; J G Bender; E T Papoutsakis
Journal:  Cytotechnology       Date:  1995-01       Impact factor: 2.058

Review 3.  Heparan sulfate proteoglycans: a GAGgle of skeletal-hematopoietic regulators.

Authors:  Kathryn D Rodgers; James D San Antonio; Olena Jacenko
Journal:  Dev Dyn       Date:  2008-10       Impact factor: 3.780

4.  Human chemokines: enhancement of specific activity and effects in vitro on normal and leukemic progenitors and a factor-dependent cell line and in vivo in mice.

Authors:  H E Broxmeyer; S Cooper; N Hague; L Benninger; A Sarris; K Cornetta; S Vadhan-Raj; P Hendrie; C Mantel
Journal:  Ann Hematol       Date:  1995-11       Impact factor: 3.673

5.  Preferential proliferation of murine colony-forming units in culture in a chemically defined condition with a macrophage colony-stimulating factor-negative stromal cell clone.

Authors:  N Takakura; H Kodama; S Nishikawa; S Nishikawa
Journal:  J Exp Med       Date:  1996-12-01       Impact factor: 14.307

6.  BB-10010/MIP-1 alpha in vivo maintains haemopoietic recovery following repeated cycles of sublethal irradiation.

Authors:  B I Lord; E Marshall; L B Woolford; M G Hunter
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

Review 7.  Role of macrophage inflammatory protein (MIP)-1α/CCL3 in leukemogenesis.

Authors:  Tomohisa Baba; Naofumi Mukaida
Journal:  Mol Cell Oncol       Date:  2014-07-15

Review 8.  Chemokines as a Conductor of Bone Marrow Microenvironment in Chronic Myeloid Leukemia.

Authors:  Naofumi Mukaida; Yamato Tanabe; Tomohisa Baba
Journal:  Int J Mol Sci       Date:  2017-08-22       Impact factor: 5.923

9.  HCC-1, a novel chemokine from human plasma.

Authors:  P Schulz-Knappe; H J Mägert; B Dewald; M Meyer; Y Cetin; M Kubbies; J Tomeczkowski; K Kirchhoff; M Raida; K Adermann; A Kist; M Reinecke; R Sillard; A Pardigol; M Uguccioni; M Baggiolini; W G Forssmann
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.